MACo Associate Director, Natasha Mehu, provided written testimony in support of legislation (SB 868), which would provide easier access to naloxone, a medication that can counter an overdose, to individuals who are most able to assist someone at risk of dying from an opioid death when emergency medical services or first responders are not readily available.
MACo’s testimony states,
SB 868 authorizes naloxone to be prescribed, dispensed, received, possessed, or administered to an individual that has not received training or certification through an overdose response program. Currently, community members must receive hands-on training and certification through the Department of Health and Mental Hygiene’s (DHMH) Overdose Response Program (ORP) in order to receive the life-saving medication without a prescription. The bill will make it easier for community members to have access to naloxone in cases where they are unable to attend a training through the ORP.
Naloxone is a safe means of saving lives. It is approved by the Food and Drug Administration (FDA) to help prevent overdoses by opioids such as heroin, morphine, and oxycodone by blocking opioid receptor sites, reversing the toxic effects of the overdose. It is not a controlled dangerous substance. There are no adverse effects from use nor does it have any potential for abuse, physical dependence, or overdose. It will neither help nor cause harm if used on someone who is not overdosing from opioids.
The cross-file to this bill (HB 791) was heard by the House Health and Government Operations committee on February 21, 2017. Click here for previous Conduit Street coverage.
Follow MACo’s advocacy efforts during the 2017 legislative session here.